Interstitial Cystitis | Unmet Need | US/EU | 2018

Interstitial cystitis/bladder pain syndrome (ICBPS) is a disorder characterized by chronic pain, discomfort, and pressure in the pelvic region that often includes symptoms of urinary frequency and urgency. Janssen/bene-Arzneimittel’s Elmiron and Mylan’s intravesical dimethyl sulfoxide (RIMSO-50) are the only two pharmacological treatments approved for ICBPS, but other antihistamines, antidepressants, and antiepileptics may be used off-label to ameliorate symptoms. Because pharmacological treatments are usually only partially effective, they are often combined with nonpharmacological therapies in a trial-and-error approach. As such, substantial unmet need persists for more effective treatment options.

QUESTIONS ANSWERED

• What are the treatment drivers and goals for ICBPS?
• What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
• How do current therapies perform on key treatment drivers and goals for ICBPS?
• What are the prevailing areas of unmet need and opportunity in ICBPS?
• What trade-offs across different clinical attributes and price are acceptable to U.S. and European urologists for a hypothetical new ICBPS drug?

PRODUCT DESCRIPTION

Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European urologists fielded in March 2018.

Key companies: bene-Arzneimittel, Janssen, Mylan, Pfizer.

Key drugs: Elmiron, amitriptyline, hydroxyzine, duloxetine, Lyrica, gabapentin, intravesical medications (lidocaine, heparin, dimethyl sulfoxide, hyaluronic acid, others).

Key metrics included:

• Stated versus derived analysis of U.S. and European physician prescribing behavior.
• Conjoint analysis with U.S. and European physicians, including market simulator.
• Assessment of current drug performance against treatment drivers and goals.
• Physician perceptions of unmet need in disease/subpopulation covered and related diseases/subpopulations.